Jazz Pharmaceuticals revenue and financials

JAZZ · NASDAQ · USD

$231.39−1.97%−$4.65

Close · October 6, 2026

In the fiscal year ended December 2025, Jazz Pharmaceuticals reported revenue of $4.27B (+4.88% year over year). The net loss was $356.15M.

Annual revenue · 2025: $4.27B

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	11,081	11,860	11,659	11,356	10,944	11,535	12,012	12,256	11,362	11,327	11,393	11,204
Current assets	3,968	4,583	4,166	3,756	3,350	4,128	4,629	4,390	3,682	3,540	3,435	3,246
Cash and equivalents	1,620	1,844	1,392	1,326	1,190	1,862	2,413	2,218	1,356	1,443	1,506	1,336
Short-term investments	580	1,030	1,050	720	480	710	580	400	625	375	120	250
Receivables	881	836	831	764	714	653	717	724	698	707	706	628
Inventory	443	438	417	483	505	493	480	539	543	577	597	612
Net property, plant and equipment	264	259	259	250	248	228	227	254	242	228	235	288
Goodwill	1,800	1,805	1,829	1,827	1,844	1,760	1,716	1,805	1,736	1,739	1,753	1,705
Other intangible assets	4,030	4,204	4,430	4,566	4,769	4,718	4,756	5,144	5,079	5,235	5,418	5,418
Long-term investments	4.3	4.3	4.3	4.3	4.3	4.3	4.3	4.3	5.1	4.7	4.7	8.2
Current liabilities	2,231	2,247	2,243	2,274	2,071	1,223	1,039	1,030	1,556	1,562	1,537	1,573
Accounts payable	129	100	122	152	89.4	95.9	77.9	85.4	97.1	81.0	103	110
Long-term debt	3,335	4,324	4,328	4,332	4,336	5,337	6,078	6,083	5,101	5,105	5,111	5,111
Total debt	4,409	5,417	5,424	5,429	5,433	—	—	—	—	—	—	—
Total liabilities	6,279	7,327	7,341	7,397	7,238	7,360	7,919	8,085	7,599	7,631	7,656	7,715
Total equity (incl. minority)	4,802	4,532	4,319	3,959	3,706	4,175	4,094	4,171	3,763	3,696	3,737	3,489
Retained earnings	1,132	939	646	443	191	1,035	1,127	936	871	864	879	884